The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 674.50
Bid: 677.50
Ask: 678.50
Change: -4.50 (-0.66%)
Spread: 1.00 (0.148%)
Open: 676.50
High: 686.00
Low: 674.50
Prev. Close: 679.00
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Vivid Sehgal Appointed Chief Financial Officer

21 Jan 2021 07:00

RNS Number : 3654M
Tate & Lyle PLC
21 January 2021
 

 

 

 

Tate & Lyle PLC - 21 January 2021

 

Vivid Sehgal Appointed Chief Financial Officer of Tate & Lyle PLC

 

Tate & Lyle PLC (Tate & Lyle) is pleased to announce the appointment of Vivid Sehgal to the position of Chief Financial Officer with effect from 1 May 2021.

 

Vivid will join Tate & Lyle as Chief Financial Officer Designate, and be appointed to the Board of Directors, from 1 March 2021. Over the following two months he will work with Imran Nawaz, the current Chief Financial Officer, to ensure a smooth transition before Imran leaves Tate & Lyle, as announced on 7 October 2020, to take up the position of Chief Financial Officer of Tesco plc.

 

Vivid Sehgal is a former Chief Financial Officer of Delphi Technologies PLC, a global provider of automotive propulsion technologies, having served from 2017 to 2020 when it was acquired by BorgWarner Inc. He also served as Chief Financial Officer of LivaNova PLC, a global medical technology company, from 2015 to 2017 and has previously held senior management positions in Allergan Inc., Gillette Inc., and GlaxoSmithKline PLC working across the US, Europe and the Middle East.

 

Nick Hampton, Chief Executive said: "I am delighted to welcome Vivid to Tate & Lyle and the executive team. He brings with him a proven track record of financial leadership as well as extensive commercial and transactional experience. I very much look forward to working with him as we continue to progress Tate & Lyle's growth agenda."

 

Gerry Murphy, Chairman said: "Vivid's broad financial, business and international experience will be of great value to Tate & Lyle and he is a very welcome addition to our Board."

 

End

 

For more information contact Tate & Lyle PLC

 

Christopher Marsh, VP Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

 

Nick Hasell, FTI Consulting (Media)

Tel: Mobile: +44 (0) 7825 523 383

 

Notes:

 

1) Vivid Sehgal's Biography

 

Vivid Sehgal, 52, was Chief Financial Officer of Delphi Technologies PLC, a global provider of automotive propulsion technologies, from 2017 until it was acquired by BorgWarner Inc. in 2020. Prior to joining Delphi, he served as Chief Financial Officer of LivaNova PLC, a global medical technology company, from 2015 to 2017. Previously, Vivid served as Senior Vice President, Treasury, Risk and Investor Relations at Allergan, Inc. a multi-specialty health care company, from 2014 to 2015. Prior to assuming his position as Senior Vice President, Mr. Sehgal served as Vice President and Regional Controller of Allergan's Europe, Middle East and Africa business from 2007 to 2014. Before Allergan, Mr. Sehgal worked for nine years in various roles with GlaxoSmithKline PLC and SmithKline Beecham PLC, where he eventually served as Group Controller for GSK's International Pharmaceutical Division. In his early career, he worked for Gillette Company, Inc. during its acquisition by Procter and Gamble, Inc. and Grand Metropolitan plc. Vivid has a Masters degree in Finance and Investment from the University of Exeter, a Bachelor's degree in Economics from the University of Leicester and is a member of the Chartered Institute of Management Accountants.

 

For rights free photos of Vivid Sehgal, please contact mediarelations@tateandlyle.com or call Anna Taylor-Elphick, Corporate PR Manager at Tate & Lyle on +44 (0)7766 361 515.

 

2) Remuneration Arrangements

 

Vivid Sehgal is appointed on an annual salary of £475,000. This will next be reviewed in April 2022. He will be eligible for a bonus under Tate & Lyle's discretionary bonus scheme. This scheme currently provides for a bonus paid at 75% of salary at target and a maximum opportunity of 150% of salary. Bonus awards are subject to performance conditions and awards in excess of 100% of salary are currently made as shares which are released after 24 months.

 

Vivid will be eligible to receive a Performance Share Plan (PSP) award of up to 300% (maximum) of base salary which will be subject to a three-year performance period. A two-year post-vesting holding period follows the three-year performance period. No other share awards are due in relation to his appointment. He is required to accumulate a shareholding in Tate & Lyle equivalent to three times base salary within five years of joining the Company.

 

3) Disclosures

 

In accordance with paragraph 9.6.13 of the Financial Conduct Authority's Listing Rules, the Company confirms that:

 

i) Vivid Sehgal holds no current directorships and has not held any directorships in the last five years in any publicly quoted companies; and

 

ii) There are no further disclosures to be made pursuant to paragraph 9.6.13 of the Financial Conduct Authority's Listing Rules.

 

4) About Tate & Lyle

 

Tate & Lyle PLC is a leading global provider of food and beverage ingredients and solutions. Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day. Through our expertise in sweetening, mouthfeel and fibre fortification, our Food & Beverage Solutions business develops solutions which reduce sugar, calories and fat, add fibre, and provide texture and stability in categories including beverages, dairy, bakery, soups, sauces and dressings. Our Primary Products business produces nutritive sweeteners, industrial starches used in paper and packaging, acidulants and products used for animal nutrition.

 

We have around 4,200 employees working in more than 60 locations across 30 countries. Tate & Lyle's purpose is Improving Lives for Generations and through our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2020, Tate & Lyle sales totaled £2.9 billion. For more information, please visit http://www.tateandlyle.com or follow Tate & Lyle on Twitter or Linkedin.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADKKBPPBKDADB
Date   Source Headline
8th May 20243:15 pmRNSHolding(s) in Company
1st May 20242:30 pmRNSTotal Voting Rights
25th Apr 20243:45 pmRNSHolding(s) in Company
24th Apr 20247:00 amRNSDirectorate Change
22nd Apr 20242:30 pmRNSDirector/PDMR Shareholding
19th Apr 202410:15 amRNSHolding(s) in Company
17th Apr 20244:15 pmRNSHolding(s) in Company
17th Apr 202410:30 amRNSHolding(s) in Company
15th Apr 202410:30 amRNSHolding(s) in Company
10th Apr 20243:45 pmRNSHolding(s) in Company
8th Apr 202411:15 amRNSHolding(s) in Company
5th Apr 20243:45 pmRNSHolding(s) in Company
4th Apr 20244:15 pmRNSHolding(s) in Company
4th Apr 202412:30 pmRNSHolding(s) in Company
4th Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 202412:45 pmRNSTotal Voting Rights
2nd Apr 202411:30 amRNSHolding(s) in Company
28th Mar 202411:45 amRNSHolding(s) in Company
25th Mar 202411:45 amRNSHolding(s) in Company
21st Mar 20244:10 pmRNSHolding(s) in Company
20th Mar 20243:00 pmRNSHolding(s) in Company
20th Mar 202412:00 pmRNSHolding(s) in Company
19th Mar 20242:00 pmRNSHolding(s) in Company
13th Mar 20244:00 pmRNSHolding(s) in Company
12th Mar 20244:24 pmRNSHolding(s) in Company
12th Mar 20244:22 pmRNSHolding(s) in Company
7th Mar 20247:00 amRNSDirectorate Change
4th Mar 20242:00 pmRNSDirector/PDMR Shareholding
4th Mar 20241:45 pmRNSHolding(s) in Company
28th Feb 20242:30 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSTrading Statement
1st Feb 202412:00 pmRNSTotal Voting Rights
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:00 pmRNSBlock listing Interim Review
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company
23rd Nov 20232:30 pmRNSHolding(s) in Company
20th Nov 202310:00 amRNSHolding(s) in Company
9th Nov 20237:00 amRNSHalf-year Report
8th Nov 20237:00 amRNSDirectorate Change
23rd Oct 202310:30 amRNSHolding(s) in Company
16th Oct 202310:30 amRNSHolding(s) in Company
13th Oct 202310:30 amRNSHolding(s) in Company
12th Oct 202311:00 amRNSHolding(s) in Company
2nd Oct 202310:23 amRNSDirector Declaration
1st Sep 202311:00 amRNSTotal Voting Rights
25th Aug 20233:45 pmRNSHolding(s) in Company
17th Aug 20234:30 pmRNSHolding(s) in Company
15th Aug 20234:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.